

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Eiji Sunahara et al.

Application No.: 10/584,183

Confirmation No.: 1851

Filed: June 23, 2006

Art Unit: N/A

For: PREVENTIVE/REMEDY FOR CANCER

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

Due to the size of references BA-BJ, Applicants have enclosed two (2) CD Roms which contains references BA-BJ and CA-CB.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 65792(46342). A duplicate copy of this paper is enclosed.

Dated: January 3, 2007

Respectfully submitted,

By 

Lisa Swiszc Hazzard

Registration No.: 44,368

EDWARDS ANGELL PALMER & DODGE  
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant

Substitute for form 1449/PTO  <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>			<b>Complete if Known</b>		
Sheet	1	of	1	Application Number	10/584,183
				Filing Date	June 23, 2006
				First Named Inventor	Eiji Sunahara
				Art Unit	1643
				Examiner Name	Not Yet Assigned A. Holleran
				Attorney Docket Number	65792(46342)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<div style="display: flex; align-items: center; justify-content: center;"> <div style="writing-mode: vertical-rl; transform: rotate(180deg); font-weight: bold; margin-right: 5px;">↓</div> <div style="font-size: 2em; font-weight: bold; margin-right: 5px;">A.H.</div> </div>	BA	WO-00/78961	12-28-2000	GENENTECH, INC.	
	BB	WO-01/36440	05-25-2001	HUMAN GENOME SCIENCES, INC.	
	BC	WO-01/77137	10-18-2001	HUMAN GENOME SCIENCES, INC.	
	BD	WO-02/06329	01-24-2002	CURAGEN CORPORATION	
	BE	WO-02/086443	10-31-2002	EOS BIOTECHNOLOGY, INC.	
	BF	WO-04/058817	07-15-2004	TAKEDA CHEMICAL INDUSTRIES, LTD.	
	BG	WO-00/12708	03-09-2000	GENENTECH, INC.	
	BH	WO-01/68848	09-20-2001	GENENTECH, INC.	
	BI	WO-02/46465	06-13-2002	OXFORD BIOMEDICA (UK) LIMITED	
	BJ	WO-02/052005	07-04-2002	KAZUSA DNA RESEARCH INSTITUTE FOUNDATION	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
<div style="display: flex; align-items: center; justify-content: center;"> <div style="writing-mode: vertical-rl; transform: rotate(180deg); font-weight: bold; margin-right: 5px;">↓</div> <div style="font-size: 2em; font-weight: bold; margin-right: 5px;">A.H.</div> </div>	CA	L. Tamagnone, et al., "Plexins Are a Large Family of Receptors for Transmembrane, Secreted, and GPI-Anchored Semaphorins in Vertebrates," <i>Cell</i> , Vol. 99, pp. 71-80 (Oct. 1, 1999).		
	CB	S. Giordano, et al., "The Semaphorin 4D receptor controls invasive growth by coupling with Met," <i>Nature Cell Biology</i> , Vol. 4, pp. 720-724 (September 2002).		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Anne Holleran/	Date Considered	03/10/2009
--------------------	-----------------	-----------------	------------

583055

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.H./